PMID- 16817691
OWN - NLM
STAT- MEDLINE
DCOM- 20060809
LR  - 20201212
IS  - 1092-0684 (Electronic)
IS  - 1092-0684 (Linking)
VI  - 9
IP  - 6
DP  - 2000 Dec 15
TI  - Treatment of a patient by vaccination with autologous dendritic cells pulsed with 
      allogeneic major histocompatibility complex class I-matched tumor peptides. Case 
      Report.
PG  - e8
AB  - Dendritic cells (DCs) are antigen-presenting cells that play a central role in 
      the initiation and modulation of antitumor immune responses. In this pilot study, 
      we investigated the ability of autologous DCs pulsed ex vivo with allogeneic 
      major histocompatibility complex class I-matched glioblastoma peptides to 
      stimulate host antitumor immune responses when injected as a vaccine. A patient 
      with recurrent brainstem glioblastoma multiforme (GBM) received a series of three 
      intradermal immunizations of antigen-pulsed DCs on an outpatient basis following 
      surgical debulking of her posterior fossa tumor. Dendritic cell vaccination was 
      well tolerated, and no clinical signs of autoimmunity or experimental allergic 
      encephalomyelitis were detected. She developed a measurable cellular immune 
      response against the allogeneic glioblastoma peptides used in her vaccine 
      preparation, as demonstrated by in vitro T-cell proliferation assays. In 
      addition, increased T-cell infiltration was noted within the intracranial tumor 
      site in the biopsy sample obtained following DC vaccination. An objective 
      clinical response, however, was not evident, and this patient eventually died 21 
      months after her disease was diagnosed. To our knowledge, this is the first 
      patient with brain cancer ever to be treated with DC-based immunotherapy. This 
      case illustrates that vaccination with DCs pulsed with acid-eluted glioblastoma 
      peptides is feasible and can induce systemic antigen-specific immunity in a 
      patient with recurrent GBM. Additional studies are necessary to determine the 
      optimum DC doses and antigen loading conditions that may translate into clinical 
      effectiveness and survival benefit for patients with brain tumors. Phase I trials 
      for malignant glioma are currently underway.
FAU - Liau, L M
AU  - Liau LM
AD  - Division of Neurosurgery, Department of Neurology, University of California at 
      Los Angeles School of Medicine, Los Angeles, California 90095-6901, USA. 
      lliau@mednet.ucla.edu
FAU - Black, K L
AU  - Black KL
FAU - Martin, N A
AU  - Martin NA
FAU - Sykes, S N
AU  - Sykes SN
FAU - Bronstein, J M
AU  - Bronstein JM
FAU - Jouben-Steele, L
AU  - Jouben-Steele L
FAU - Mischel, P S
AU  - Mischel PS
FAU - Belldegrun, A
AU  - Belldegrun A
FAU - Cloughesy, T F
AU  - Cloughesy TF
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20001215
PL  - United States
TA  - Neurosurg Focus
JT  - Neurosurgical focus
JID - 100896471
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Cancer Vaccines)
RN  - 0 (Histocompatibility Antigens Class I)
SB  - IM
MH  - Antigens, Neoplasm/immunology
MH  - Brain Neoplasms/immunology/pathology/*therapy
MH  - Cancer Vaccines/administration & dosage/immunology
MH  - Dendritic Cells/*immunology/transplantation
MH  - Fatal Outcome
MH  - Female
MH  - Glioblastoma/immunology/pathology/*therapy
MH  - Histocompatibility Antigens Class I/*immunology
MH  - Humans
MH  - Immunotherapy, Adoptive/*methods
MH  - Magnetic Resonance Imaging
MH  - Middle Aged
EDAT- 2006/07/05 09:00
MHDA- 2006/08/10 09:00
CRDT- 2006/07/05 09:00
PHST- 2006/07/05 09:00 [pubmed]
PHST- 2006/08/10 09:00 [medline]
PHST- 2006/07/05 09:00 [entrez]
AID - 090608 [pii]
AID - 10.3171/foc.2000.9.6.9 [doi]
PST - epublish
SO  - Neurosurg Focus. 2000 Dec 15;9(6):e8. doi: 10.3171/foc.2000.9.6.9.